(RTTNews) - Sage Therapeutics, Inc. (Sage) announced Thursday that Biogen Inc. (BIIB) has terminated its rights under the collaboration and license agreement specific to the SAGE-324 program. Under ...
Sage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program
Sage and Biogen will continue to partner on ZURZUVAE®, the first and only FDA-approved oral treatment for women with postpartum depression CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics, Inc.
Todd Young was first to speak at Monday’s Holmen School Board meeting. A parent, he said that the state-sponsored SAGE program at Viking Elementary keeps class sizes small and allowed his third-grade ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results